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Lipocalin 2 as a potential systemic 
biomarker for central serous 
chorioretinopathy
A. Matet1,2,3,12, T. Jaworski1,12, E. Bousquet1,2,4, J. Canonica1,5, C. Gobeaux6, A. Daruich1,2,7, 
M. Zhao1, M. Zola1,5, M. Meester‑Smoor8, D. Mohabati9,10, F. Jaisser1, S. Yzer9,11,12 & 
F. Behar‑Cohen1,2,4,12*
No systemic biomarker of Central Serous Chorioretinopathy (CSCR) has been identified. Lipocalin 
2 (LCN2 or NGAL), alone or complexed with MMP‑9 (NGAL/MMP‑9), is increased in several retinal 
disorders. Serum levels of LCN2 and NGAL/MMP‑9 were measured in CSCR patients (n = 147) with 
chronic (n = 76) or acute/recurrent disease (n = 71) and in age‑ and sex‑matched healthy controls 
(n = 130). Samples with CRP > 5 mg/L, creatinine > 100 µmol/L, and/or urea > 7.5 mmol/L were excluded. 
Serum LCN2 was lower in CSCR patients than controls (81.4 ± 48.7 vs 107.3 ± 44.5 ng/ml, p < 0.0001), 
and lower in acute/recurrent CSCR than controls (p < 0.001) and chronic CSCR (p = 0.006). Serum NGAL/
MMP‑9 was lower in CSCR patients than controls (47.2 ± 40.7 vs 74.1 ± 42.6, p < 0.0001), and lower in 
acute/recurrent CSCR than controls (p < 0.001) and chronic CSCR (p = 0.002). A ROC curve showed that 
for LCN2 serum levels, the 80‑ng/ml cutoff value allows to discriminate acute/recurrent CSCR from 
controls with 80.3% sensitivity and 75.8% specificity, and for NGAL/MMP‑9 serum levels, a 38‑ng/
ml cutoff value allows to discriminate acute/recurrent CSCR from controls with 69.6% sensitivity 
and 80.3% specificity. In both acute and chronic CSCR, low serum LCN2 and NGAL/MMP‑9, provide a 
biological link between the two CSCR forms, and potential susceptibility to oxidative stress and innate 
immune dysregulation in CSCR.
Central serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal 
pigment epithelium (RPE). Different forms of the disease are recognized although a consensus nomenclature 
is still  missing1. Most of the patients present with a focal RPE leak that causes a spontaneously resolving, and 
sometimes recurrent serous detachment. In a minority of patients, widespread retinal pigment epitheliopathy, 
and/or persistent serous detachments, result in severe visual impairment and anatomical  complications2. The 
exact mechanisms and the causative factors for the disease remain uncertain. The most widely recognized risk 
factors for CSCR include exposure to exogenous or endogenous corticosteroids, psychopharmacologic medica-
tion use and type A personality, sleep disorders, shift work, helicobacter pylori infection, and cardiovascular 
risk factors such as hypertension and coronary heart  disease3. Genetic predisposing factors have been identified, 
such as polymorphism in genes encoding complement factor system  regulators4, the mineralocorticoid  receptor5, 
plasminogen  activators6 and VIP  receptor7. For typical presentations the diagnosis of CSCR is usually straight-
forward, based on clinical imaging features, such as spectral domain optical coherence tomography (SD-OCT), 
fluorescein angiography (FA) and indocyanine green (ICG) angiography. However, it can be challenging in 
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atypical cases, particularly in women, subjects with thin choroid on SD-OCT or those without favoring factors. 
To the best of our knowledge, no systemic biomarker of CSCR has been identified to date.
Lipocalin-2 (LCN2), whose human ortholog is Neutrophil Gelatinase-Associated Lipocalin (NGAL), is a 
25-kD secreted protein, expressed in numerous cell types and organ systems, such as innate immune cells, 
epithelial cells, and brain astrocytes. In the eye, it is expressed in retinal pigment epithelial  cells8 and in retinal 
glial Müller cells 9. LCN2 is induced in response to acute injury, infection and metabolic disturbance by NF-κB 
 activation10,11. However, depending on the disease phase (acute vs chronic) and on the injured organ, LCN2 
exerts pro- or anti-inflammatory effects. In transgenic mice with defective lysosome-mediated clearance in RPE 
cells, harboring phenotypic features of early age-related macular degeneration, LCN2 produced by neutrophils 
enhances their retinal infiltration, contributing to age-related  changes12. On the other hand, in  brain13 and eye 
models of lipopolysaccharide-induced inflammation, LCN2 reduced inflammation through the inactivation of 
NF-κB9. An additional function of LCN2 is to promote matrix metallopeptidase 9 (MMP-9) activity by forming 
a complex with the protease (NGAL/MMP-9)14.
In the retina, the role of LCN2 is incompletely understood. It is the most expressed early-stress gene in the 
RPE and the neurosensory retina of Abca4-/- Rdh8-/- mice overexposed to light, a model of AMD. In this model, 
LCN2 protected from gliosis and microglial activation, as shown in Lcn2-/- Abca4-/- Rdh8-/-  mice8,15. In addition, 
LCN2 protected human RPE cells derived from induced pluripotent stem cells (iPS-RPE cells) against oxida-
tive stress by increasing the expression of the antioxidant enzymes HMOX1 (Heme oxygenase 1) and SOD2 
(superoxide dismutase 2)15, suggesting that LCN2 exerts important neuroprotective effects in the outer retina.
LCN2 is employed as a biomarker for several inflammatory and metabolic  diseases16, and is recognized as one 
of the best diagnostic and prognostic marker for acute kidney  injury17–21. LCN2 is also a biomarker for athero-
sclerosis, myocardial infarction and heart  failure22. After myocardial infarction, LCN2 produced by neutrophils 
induces the polarization of macrophages towards a phenotype that allows clearance of apoptotic cells and reduces 
cardiac fibrosis. LCN2 is thus beneficial for cardiac remodeling 23.
In ocular diseases, systemic and local LCN2 levels have also been measured. In central retinal vein occlusion, 
LCN2 is increased in aqueous humor but not in  serum24. In diabetic retinopathy, plasma LCN2 levels are elevated 
and correlate with the severity of  retinopathy25. In AMD, plasma LCN2 levels are elevated and LCN2 is increased 
in aqueous humor of patients with wet  AMD26. To our knowledge, no study has measured the systemic levels of 
LCN2 or NGAL/MMP-9 in CSCR. The primary aim of this study was to investigate the potential of LCN2 and 
NGAL/MMP-9 as biomarkers for CSCR. Therefore, we compared serum LCN2 levels in subjects with different 
forms of CSCR, and in healthy controls.
Subjects and methods
Patients were included from 3 cohorts recruited at the Jules-Gonin Eye Hospital (Lausanne, Switzerland), the 
Ophthalmopole Cochin hospital (Paris, France) and the Rotterdam Eye Hospital (Rotterdam, Netherland). The 
cases selection was based on the availability of samples from patients with well-defined phenotypes based on 
multimodal retinal imaging.
The study is a cohort case–control retrospective study. Diagnostic criteria for CSCR were defined on multi-
modal imaging including FAF, spectral-domain optical coherence tomography (SD-OCT, Spectralis, Heidelberg 
Engineering, Heidelberg, Germany) and FA. Patients were divided in two groups based on the disease history 
and/or the presence of an underlying multifocal epitheliopathy as observed on FAF and on FA. Patients with 
epitheliopathy (total cumulated area > 2 disc diameters) were classified as chronic cases, while patients without 
epitheliopathy were classified as acute/recurrent cases (Fig. 1). ICG angiography was performed in all patients 
in Paris and Lausanne clinics and only in patients with epitheliopathy to exclude choroidal neovascularization 
or for treatment guidance according to the decision of the attending clinician. Patients with any other ocular 
disease, such as age-related macular degeneration (characterized by the presence of drusens), diabetic retinopa-
thy, retinal vein occlusion, high myopia > -6D, or glaucoma were excluded from the study. Since OCT-A was 
not available in all clinics at the time of cohorts constitution, choroidal neovascularization (CNV) secondary to 
CSCR could not be excluded with certainty, although patients suspected of CNV on SD-OCT were excluded if 
CNV was confirmed on ICG.
Serum samples were withdrawn at different hours during the day depending on clinic organization since 
previous study did not found any circadian influence on systemic LCL2  levels27. All patients had an active 
episode of CSCR at the time of blood sampling defined as the presence of subretinal fluid. Serum samples from 
control subjects were obtained from the Banque Française du Sang (BFS) under an agreement between BFS and 
Inserm. Blood samples were collected from donors aged between 20 and 60 years, preferentially men who had 
no previous history of ocular diseases to match with the age and sex ratio of the CSCR patients, although no 
significant correlations between systemic LCN2 levels and age or sex have been observed in other  cohorts28,29.
Ethics statement. This research was conducted in compliance with the tenets of the Declaration of Hel-
sinki and was approved by the competent institutional review boards in France (Comité de Protection des Per-
sonnes CPP Ile de France 1, protocole C16-09 N°DC-2016–2620), Switzerland (La Commission cantonale (VD) 
d’éthique de la recherche sur l’être humain (CER -VD) Eyeomics340/15) and in the Netherlands (Medische 
Ethische Toetsingscommissie Leids Universitair Medisch Centrum, NL50816.058.14). Written informed con-
sent was obtained from each patient and healthy participant.
LCN2 and NGAL/MMP‑9 serum level measurements. Human Lipocalin-2/NGAL Quantikine ELISA 
Kit and Human MMP-9/NGAL Complex Quantikine ELISA Kit (R &D Systems, catalog number DLCN20 and 
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DM9L20 respectively, Minneapolis, MN) were used to measure NGAL and NGAL/MMP-9 complex according 
to the manufacturer protocol. All samples were tested in duplicated and required a 20-Fold dilution.
Because LCN2 levels are influenced by kidney  function21 and by inflammatory  state16, patients with 
CRP > 5 mg/L, creatinine > 100 µmol/L, urea > 7.5 mmol/L were excluded (53 and 24 subjects were excluded 
in the CSCR and control groups, respectively). ELISA analyses were performed in Paris in 2019 by JC and TJ 
blind to diagnoses.
Statistics. Descriptive, comparative and correlative statistics were computed on XLstat software (version 
2014.6.01; Addinsoft, Paris, France). Quantitative values were expressed as mean ± standard deviation. Categori-
cal variables were presented as counts and percentage. The Kolmogorov–Smirnov test was employed to assess 
the normal or non-normal distribution of quantitative values. The Mann–Whitney test or the Kruskal–Wallis 
test with post hoc Dunn test were employed to compare quantitative values. The Chi-square test was employed 
to compare proportions. Receiver operating characteristics (ROC) curves were plotted and analyzed to assess the 
sensitivity, specificity, and cutoff values of serum marker levels. The optimal cutoff was found using the Youden 
index. P values inferior to 0.05 were considered significant.
Results
Demographic characteristics. The demographic characteristics of 147 patients with CSCR and 130 
healthy control subjects are shown in Table 1. Mean age and sex ratio did not differ statistically between the 
CSCR and control groups. In the CSCR group, 71 patients (48%) presented an acute or recurrent form of the 
disease, while 76 patients (52%) presented a chronic form of the disease with epitheliopathy.
Serum levels of LCN2 (NGAL) and NGAL/MMP‑9 are lower in CSCR than in control sub‑
jects. Serum levels of LCN2 (NGAL) and the LCN2/MMP-9 (NGAL/MMP-9) complex are shown in Table 1, 
Table  2 and in Fig.  2. Serum NGAL was significantly lower in the CSCR cohort than in the control group 
(81 ± 48.7 ng/ml vs 107.3 ± 44.5 ng/ml respectively, p < 0.0001, Table 1). In patients with CSCR, serum NGAL 
level was significantly lower in the acute/recurrent subgroup than in the chronic subgroup (p = 0.006, Table 2). 
In both forms of CSCR, NGAL level was lower than in the control group (p < 0.001, Table 2).
Similarly, serum NGAL/MMP-9 levels were significantly lower in CSCR patients as compared to controls 
(47.2 ± 40.7 ng/ml vs 74.1 ± 42.6 ng/ml, respectively, p < 0.0001, Table 1). Serum NGAL/MMP-9 level was signifi-
cantly lower in the acute/recurrent CSCR subgroup than in the chronic CSCR subgroup (p = 0.002, Table 2). In 
both forms of CSCR, NGAL/MMP-9 level was lower than in the control group (p < 0.001, Table 2).
ROC curve analysis. As displayed in Fig. 3, a ROC curve analysis showed that for serum levels of LCN2 
(NGAL), an optimal cutoff value (Youden index) of 80 ng/mL allowed to discriminate acute/recurrent CSCR 
Figure 1.  Representative horizontal cross sections of the retina on an enhanced depth imaging spectral domain 
OCT in an acute central serous chorioretinopathy (CSCR) (A), and a chronic CSCR (B) patient. On the blue 
autofluorescence imaging there is limited retinal pigment epithelium (RPE) alteration (< 2 disc diameters) in the 
acute CSCR (A), while in the chronic CSCR (B), an extended area of pigment epithelium alteration is observed.
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(< 80 ng/mL) from controls (≥ 80 ng/mL) with 80.3% sensitivity and 75.8% specificity. For serum levels of the 
NGAL/MMP-9 complex, the optimal cutoff value (Youden index) of 38 ng/mL allowed to discriminate acute/
recurrent CSCR (< 38 ng/mL) from controls (≥ 38 ng/mL) with 69.6% sensitivity and 80.3% specificity.
Discussion
In this study, we observed that patients with CSCR have lower serum levels of LCN2 (NGAL) and NGAL/MMP-9 
than control subjects. The fact that patients originate from 3 different cohorts reinforce the strength of this unex-
pected finding. Serum levels measured in control subjects from the present study are in the range measured in 
Table 1.  Data of patients with central serous chorioretinopathy (CSCR) and healthy controls included in the 
study. a Mann-Whitney U test; bKhi2 test. NGAL: Neutrophil Gelatinase-Associated Lipocalin. MMP-9: Matrix 
metallopeptidase 9. Bold p values indicate different groups
Group CSCR patients (n = 147) Healthy controls (n = 130) p value
Age, mean ± SD, years 48.7 ± 8.6 47.2 ± 10.6 0.4a
Sex ratio, male, n (%) 120 (81.6%) 103 (79.2%) 0.6b
NGAL serum level (ng/ml) 81 ± 48.7 107.3 ± 44.5  < 0.0001a
NGAL/MMP9 serum level (ng/ml) 47.2 ± 40.7 74.1 ± 42.6  < 0.0001a
Table 2.  Serum levels of NGAL and NGAL/MMP9 in patients with acute/recurrent CSCR, chronic CSCR 
and healthy controls. *Kruskal–Wallis test with post hoc Dunn test and Bonferroni correction. CSCR: 
central serous chorioretinopathy. NGAL: Neutrophil Gelatinase-Associated Lipocalin. MMP-9: Matrix 
metallopeptidase 9.
Acute/recurrent  CSCRa 
(n = 71) Chronic  CSCRb (n = 76) Healthy  controlsc (n = 130) p value*
NGAL serum level (ng/ml) 71.6 ± 33.4 89.9 ± 58.6 107.3 ± 44.5
a vs b : p = 0.006
a vs c : p < 0.001
b vs c : p < 0.001
NGAL/MMP9 serum level 
(ng /ml) 38.9 ± 38.4 54.8 ± 41.5 74.1 ± 42.6
a vs b : p = 0.002
a vs c : p < 0.001
b vs c : p < 0.001
Figure 2.  Serum NGAL (A) and NGAL/MMP-9 (B) levels (ng/ml). Mean ± SD serum levels in CSCR as 
compared to control subjects. ***p < 0.001, **p < 0.01; NGAL: Neutrophil Gelatinase-Associated Lipocalin; 
MMP-9: Matrix metallopeptidase 9.
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control populations of two previous studies (115 ± 86 ng/ml, n = 3030, and 122.53 ± 26.15 ng/ml, n = 14231). High 
systemic level of LCN2 is a biomarker of  metabolic16, cardiac 32, and acute kidney  disease18,19. Plasma LCN2 has 
been identified both as diagnostic and severity marker of diabetic  retinopathy25. Increased plasma LCN2 levels 
were also measured in patients with Stargardt disease, retinitis pigmentosa, and AMD, as compared to healthy 
 controls8. Yet, our findings surprisingly indicate that in CSCR patients LCN2 serum levels are lower compared 
to healthy controls. In addition, levels of the NGAL/MMP-9 complex are also lower, suggesting a decreased 
endogenous production of LCN2 in CSCR patients. Moreover, according to our subgroup observations, subjects 
with retinal pigment epitheliopathy (chronic CSCR), and those without RPE damage (acute/recurrent CSCR) 
have reduced LCN2 and NGAL/MMP-9 serum levels. These findings suggest a biological continuum between 
both forms of the disease and indicate a potential underlying mechanism. As compared to other organ systems, 
where LCN2 exerts rather pro-inflammatory effects, LCN2 showed anti-inflammatory and anti-oxidant effects 
in the retina, and particularly in models of pre-existing RPE pathology, such as in Abca4-/-Rdh8-/- mice submit-
ted to  light15. LCN2 was also shown to enhance the proper membrane distribution of ZO-1 and VE-Cadherin33, 
which could be important because in CSCR, RPE junctions could be disrupted. Recently, Parmar et al.showed 
that LCN2 exerted a strong dose-dependent protective effect on human iPS-RPE against  H2O2-induced cell 
death, and from inflammatory-induced apoptosis. In addition, the expression of the LCN2 receptor SLC22A17 
gene was upregulated by light in RPE cells, showing that LCN2, either produced by RPE cells or by immune cells, 
may serve to protect the retina from inflammation and oxidative stress-induced  degeneration8. Reduced serum 
LCN2 levels in CSCR patients could thus confer excessive susceptibility to oxidative stress and contribute to the 
alteration of the RPE barrier function. This is supported by the recent observation that the disulfide/thiol ratio 
is significantly greater in CSCR patients than in healthy control  subjects34.
On the other hand, low levels of the NGAL/MMP-9 complex may protect the retina from MMP-9 activity and 
subsequent leukocyte infiltration. Indeed, in the brain, MMP-9 is required for the initial infiltration of leukocytes 
through the blood–brain barrier in experimental autoimmune  encephalomyelitis35. Leukocyte infiltration in the 
retina has been observed in patients with AMD as a consequence of the AKT2-NFkB-LCN2  axis12. In CSCR, 
low MMP-9 activity could contribute to the maintenance of the inner blood-retinal barrier, despite outer retinal 
barrier breakdown.
Another interesting observation is that LCN2 is one of the rare NF-kB-induced  molecules10 that is up-reg-
ulated by  glucocorticoids36. The paradoxical predisposing and aggravating effects of glucocorticoids in CSCR, 
could result from an improper regulation of LCN2 by glucocorticoids. But, whether serum levels of LCN2 and 
NGAL/MMP-9 reflect their ocular levels, and whether these levels vary differently upon corticoid simulation in 
CSCR patients as compared to healthy controls, remain to be studied.
There are some weaknesses in this study and particularly the absence of ICG angiography and OCT-A for all 
patients included in the different clinics, due to different practice and to the fact that OCT-A was not available 
in all clinics when patients were included. Thus, we cannot exclude with certainty that some chronic patients 
did not have CNV, or a very atypical form of AMD, since OCT-A was not systematically performed in all the 
patients. Yet, the clinical diagnosis of chronic CSCR also relies on clinical history and risk factors, which differ 
from AMD patients. Systemic LCN2 being increased in patients with wet  AMD8, this could in part explain why 
complex CSCR with epitheliopathy in our study had higher LCN2 levels than acute cases. Whether LCN2 could 
help discriminate CSCR patients with CNV is currently under study. In this study, we have not investigated cor-
relations between functional clinical parameters, such as visual acuity, and LCN2, LCN2/MMP9 levels, which 
will be the subject of an ongoing prospective study.
In conclusion, the observation of decreased serum levels of NGAL (LCN2) and NGAL/MMP-9 in CSCR 
patients with and without retinal pigment epitheliopathy, provides a biologic link between the two forms of the 
disease and, suggests a potential mechanism consistent with the current understanding of the disease patho-
genesis. To our knowledge, CSCR is the only ocular disease associated with decreased LCN2 level, and therefore 
LCN2 could be potentially used as a biomarker for CSCR, particularly in atypical cases or those where the 
Figure 3.  Receiver operating characteristics (ROC) curves for NGAL (A) and NGAL/MMP-9 (B). AUC: Area 
Under the Curve. NGAL: Neutrophil Gelatinase-Associated Lipocalin; MMP-9: Matrix metallopeptidase 9.
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differential diagnosis with AMD is challenging. Further comparative studies should be conducted to confirm 
this preliminary finding.
Received: 7 April 2020; Accepted: 29 October 2020
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